How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

27,131 results for

Cervical Cancer

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Human Papillomavirus (HPV), Cervical Screening and Cervical Cancer

Human Papillomavirus (HPV), Cervical Screening and Cervical Cancer CLINICAL PROFESSIONAL RESOURCE Human Papillomavirus (HPV), Cervical Screening and Cervical Cancer RCN guidance2 Publication This is an RCN practice guidance. Practice guidance are evidence-based consensus documents, used to guide decisions about appropriate care of an individual, family or population in a specific context. Description Guidance for registered nurses working in a range of health care settings, in particular those (...) involved in womens health, cervical screening and public health. This RCN publication focuses on an overview of HPV (including the current vaccination recommendations), the national cervical screening programme, information about colposcopy and some key facts on cervical cancer. Publication date: June 2018 Review date: June 2021 The Nine Quality Standards This publication has met the nine quality standards of the quality framework for RCN professional publications. For more information, or to request

2018 Royal College of Nursing

2. General medicine: High incidence of cervical cancer in women over 60 is likely due to less intensive cervical screening in this generation of women

General medicine: High incidence of cervical cancer in women over 60 is likely due to less intensive cervical screening in this generation of women High incidence of cervical cancer in women over 60 is likely due to less intensive cervical screening in this generation of women | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use (...) cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here High incidence of cervical cancer in women over 60 is likely due to less intensive cervical screening

2018 Evidence-Based Medicine (Requires free registration)

3. Nerve-sparing radical hysterectomy compared to standard radical hysterectomy for women with early stage cervical cancer (stage Ia2 to IIa). (PubMed)

Nerve-sparing radical hysterectomy compared to standard radical hysterectomy for women with early stage cervical cancer (stage Ia2 to IIa). Radical hysterectomy is one of the standard treatments for stage Ia2 to IIa cervical cancer. Bladder dysfunction caused by disruption of the pelvic autonomic nerves is a common complication following standard radical hysterectomy and can affect quality of life significantly. Nerve-sparing radical hysterectomy is a modified radical hysterectomy, developed (...) of conferences, citation lists of included studies, and key textbooks for potentially relevant studies.We included randomised controlled trials (RCTs) evaluating the efficacy and safety of nerve-sparing radical hysterectomy compared to standard radical hysterectomy for women with early stage cervical cancer (stage Ia2 to IIa).We applied standard Cochrane methodology for data collection and analysis. Two review authors independently selected potentially relevant RCTs, extracted data, evaluated risk of bias

2019 Cochrane

4. Cervical cancer

Cervical cancer Evidence Maps - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4

2018 Trip Evidence Maps

5. Economic Analyses of Policies to Reduce Cervical Cancer

Economic Analyses of Policies to Reduce Cervical Cancer Rapid Synthesis Economic Analyses of Policies to Reduce Cervical Cancer 15 February 2019 McMaster Health Forum 1 Evidence >> Insight >> Action Rapid Synthesis: Economic Analyses of Policies to Reduce Cervical Cancer 30-day response 15 February 2019 Economic Analyses of Policies to Reduce Cervical Cancer 2 Evidence >> Insight >> Action McMaster Health Forum The McMaster Health Forum’s goal is to generate action on the pressing health-system (...) and suggestions. Citation Mattison CA, Wilson MG. Rapid synthesis: Economic analyses of policies to reduce cervical cancer. Hamilton: McMaster Health Forum, 15 February 2019. Product registration numbers ISSN 2292-7999 (online)McMaster Health Forum 3 Evidence >> Insight >> Action KEY MESSAGES Questions • What are the costs or cost-effectiveness of population-level programs and policies aimed at HPV vaccination? • What are the costs or cost-effectiveness of population-level programs and policies aimed

2019 McMaster Health Forum

6. HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence – An Update

HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence – An Update HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence – An Update | CADTH.ca Find the information you need HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence – An Update HPV Self-Sampling for Primary Cervical Cancer Screening: A Review (...) of Diagnostic Test Accuracy and Clinical Evidence – An Update Last updated: May 30, 2019 Project Number: RC1124-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the diagnostic test accuracy of self-sampled HPV tests compared with clinician-sampled HPV tests or cytology for asymptomatic cervical cancer screening? What is the clinical evidence regarding the agreement or concordance of self-sampled HPV tests and clinician

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

7. Barriers to Cervical Cancer Screening and the Cervical Cancer Care Continuum in Rural Guatemala: A Mixed-Method Analysis (PubMed)

Barriers to Cervical Cancer Screening and the Cervical Cancer Care Continuum in Rural Guatemala: A Mixed-Method Analysis Purpose Cervical cancer is an important cause of mortality in low- and middle-income countries. Although screening technologies continue to improve, systems of care remain fragmented. It is important to better understand factors that affect use of screening services and loss to follow-up along the care continuum. Methods We conducted a mixed-methods study of a cytology-based (...) screening program in rural Guatemala. A retrospective electronic chart review was performed on data from all patients from 2013 to 2014. We analyzed progression through care and calculated loss-to-follow-up rates. We also analyzed the prior experiences of patients with cervical cancer screening on the basis of self-reported historical data available in the chart review. Structured interviews with a subset of individuals to explore social supports and barriers to screening and engagement in care were

Full Text available with Trip Pro

2018 Journal of global oncology

8. Estimating the costs of HIV clinic integrated versus non-integrated treatment of pre-cancerous cervical lesions and costs of cervical cancer treatment in Kenya. (PubMed)

Estimating the costs of HIV clinic integrated versus non-integrated treatment of pre-cancerous cervical lesions and costs of cervical cancer treatment in Kenya. To estimate the modified societal costs of cervical cancer treatment in Kenya; and to compare the modified societal costs of treatment for pre-cancerous cervical lesions integrated into same-day HIV care compared to "non-integrated" treatment when the services are not coordinated on the same day.A micro-costing study was conducted (...) . From the modified societal perspective, per-procedure costs of colposcopy were $41 (integrated) vs. $91 (non-integrated). Per-procedure costs of cryotherapy were $22 (integrated) vs. $46 (non-integrated), whereas costs of LEEP were $50 (integrated) and $99 (non-integrated). This represents cost savings of $25 for cryotherapy and $50 for colposcopy and LEEP when provided on the same day as an HIV-care visit. Treatment for cervical cancer cost $1,345-$6,514, depending on stage. Facility-based

Full Text available with Trip Pro

2019 PLoS ONE

9. Comprehensive genomic variation profiling of cervical intraepithelial neoplasia and cervical cancer identifies potential targets for cervical cancer early warning

Comprehensive genomic variation profiling of cervical intraepithelial neoplasia and cervical cancer identifies potential targets for cervical cancer early warning Comprehensive genomic variation profiling of cervical intraepithelial neoplasia and cervical cancer identifies potential targets for cervical cancer early warning | JMG Contact blog by The article found some significantly mutated genes in CC using NGS technology and predicted that 55.9% of CC patients might potentially benefit from (...) targeted drugs. And HPV integrations occurred in 97.8% of the CCs, 70.5% of the CINs and 42.8% normal cervical samples with HPV infection. Integrations of high-risk HPV strains in CCs, including HPV16, 18, 33 and 58, also occurred in the CIN samples. Moreover, gene mutations were detected in 52% of CIN specimens. This article provide a strong evidence of the molecular events may serve as potential biomarker for cervical cancer screening and treatment. (By Dr Jian Huang, ) (Visited 9 times, 1 visits

2018 JMG Contact blog

12. Type II or type III radical hysterectomy compared to chemoradiotherapy as a primary intervention for stage IB2 cervical cancer. (PubMed)

Type II or type III radical hysterectomy compared to chemoradiotherapy as a primary intervention for stage IB2 cervical cancer. Cervical cancer is the fourth most common cancer in women, with 528,000 estimated new cases globally in 2012. A large majority (around 85%) of the disease burden occurs in low- and middle-income countries (LMICs), where it accounts for almost 12% of all female cancers. Treatment of stage IB2 cervical cancers, which sit between early and advanced disease (...) , is controversial. Some centres prefer to treat these cancers by radical hysterectomy, with chemoradiotherapy reserved for those at high risk of recurrence. In the UK, we treat stage IB2 cervical cancers mainly with chemoradiotherapy, based on the rationale that a high percentage will have risk factors necessitating chemoradiotherapy postsurgery. There has been no systematic review to determine the best possible evidence in managing these cancers.To determine if primary surgery for stage IB2 cervical cancer

2018 Cochrane

13. Extended-field radiotherapy for locally advanced cervical cancer. (PubMed)

Extended-field radiotherapy for locally advanced cervical cancer. The para-aortic lymph nodes (located along the major vessels in the mid and upper abdomen) are a common place for disease recurrence after treatment for locally advanced cervical cancer. The para-aortic area is not covered by standard pelvic radiotherapy fields and so treatment to the pelvis alone is inadequate for women at a high risk of occult cancer within para-aortic lymph nodes. Extended-field radiotherapy (RT) widens (...) the pelvic RT field to include the para-aortic lymph node area. Extended-field RT may improve outcomes in women with locally advanced cervical cancer by treating occult disease in para-aortic nodes not identified at pretreatment imaging. However, RT treatment of the para-aortic area can cause severe adverse effects, so may increase harms.Studies of pelvic chemoradiotherapy (CRT) demonstrated improved survival rates compared to pelvic RT alone. CRT is now the standard of care in the treatment of locally

2018 Cochrane

14. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. (PubMed)

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Persistent infection with high-risk human papillomaviruses (hrHPV) types is causally linked with the development of cervical precancer and cancer. HPV types 16 and 18 cause approximately 70% of cervical cancers worldwide.To evaluate the harms and protection of prophylactic human papillomaviruses (HPV) vaccines against cervical precancer and HPV16/18 infection in adolescent girls and women.We (...) trials (73,428 participants). Ten trials, with follow-up of 1.3 to 8 years, addressed protection against CIN/AIS. Vaccine safety was evaluated over a period of 6 months to 7 years in 23 studies. Studies were not large enough or of sufficient duration to evaluate cervical cancer outcomes. All but one of the trials was funded by the vaccine manufacturers. We judged most included trials to be at low risk of bias. Studies involved monovalent (N = 1), bivalent (N = 18), and quadrivalent vaccines (N = 7

Full Text available with Trip Pro

2018 Cochrane

15. Cervical cancer

Cervical cancer Cervical cancer - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Cervical cancer Last reviewed: February 2019 Last updated: March 2019 Important updates 19 Mar 2019 Studies suggest minimally invasive surgery for early-stage cervical cancer results in lower 4-year survival rates Women undergoing minimally invasive radical hysterectomy for early-stage cervical cancer have lower rates of disease-free (...) survival and overall survival compared with those who have open abdominal radical hysterectomy, studies with 4 years of follow-up have found. Ramirez PT, Frumovitz M, Pareja R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N Engl J Med. 2018 Oct 31;379(20):1895-1904. http://www.ncbi.nlm.nih.gov/pubmed/30380365?tool=bestpractice.com Melamed A, Margul DJ, Chen L, et al. Survival after minimally invasive radical hysterectomy for early-stage cervical cancer. N Engl J

2018 BMJ Best Practice

16. Systematic review of the relationship between hormonal contraception and cervical cancer progression/ risk of cervical cancer

Systematic review of the relationship between hormonal contraception and cervical cancer progression/ risk of cervical cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

17. Human papillomavirus 9-valent vaccine (Gardasil 9) and cervical cancer. A few cases of dysplasia prevented, but an increase in painful reactions

Human papillomavirus 9-valent vaccine (Gardasil 9) and cervical cancer. A few cases of dysplasia prevented, but an increase in painful reactions Prescrire IN ENGLISH - Spotlight ''Human papillomavirus 9-valent vaccine (Gardasil 9°) and cervical cancer. A few cases of dysplasia prevented, but an increase in painful reactions'', 1 June 2018 {1} {1} {1} | | > > > Human papillomavirus 9-valent vaccine (Gardasil 9°) and cervical cancer. A few cases of dysplasia prevented, but an increase in painful (...) reactions Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Human papillomavirus 9-valent vaccine (Gardasil 9°) and cervical cancer. A few cases of dysplasia prevented, but an increase in painful reactions FEATURED REVIEW A human papillomavirus (HPV) vaccine containing 9 HPV genotypes (Gardasil 9°) has been authorised in the European Union. The 9-valent

2018 Prescrire

18. Accuracy of Self-Report for Cervical and Breast Cancer Screening

Accuracy of Self-Report for Cervical and Breast Cancer Screening Management Briefs eBrief-no152 -- Accuracy of Self-Report for Cervical and Breast Cancer Screening Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs eBrief-no152 -- Accuracy of Self-Report for Cervical and Breast Cancer Screening Health Services Research & Development Management eBrief no. 152 » Issue 152 April 2019 (...) The report is a product of the VA/HSR&D Evidence Synthesis Program. Evidence Brief: Accuracy of Self-Report for Cervical and Breast Cancer Screening Guideline-based breast and cervical cancer screening are considered essential health benefits and are fundamental components of high-quality primary care services in the United States. The aim of cancer screening is to identify cancers in an early stage when treatment is more likely to be effective. Accurate measurement of cancer screening rates is vital

2019 Veterans Affairs - R&D

19. Emerging data on the surgical approach for radical hysterectomy in the treatment of women with cervical cancer

Emerging data on the surgical approach for radical hysterectomy in the treatment of women with cervical cancer SGO member update: Emerging data on the surgical approach for radical hysterectomy in the treatment of women with cervical cancer | SGO Secondary menu Working to Eradicate Gynecologic Cancers Main menu Search | | Are you sure you wish to delete this record?

2019 Society of Gynecologic Oncology

20. HPV Testing for Primary Cervical Cancer Screening

HPV Testing for Primary Cervical Cancer Screening HPV Testing for Primary Cervical Cancer Screening | CADTH.ca Find the information you need HPV Testing for Primary Cervical Cancer Screening HPV Testing for Primary Cervical Cancer Screening Published on: March 26, 2019 Project Number: OP0530-000 Product Line: Result type: Report Worldwide, cervical cancer is one of the most frequently diagnosed cancers; however, the incidence of cervical cancer has been decreasing in the past three decades (...) , largely due to routine screening with cytology. HPV is the major risk factor for the development of cervical cancer, with 99% of cervical cancer being associated with HPV. It is one of the most common sexually transmitted infections in the world and about three out of every four sexually active Canadians will have at least one HPV infection at some point in their lives. In view of the anticipated higher sensitivity of HPV testing, some experts and stakeholders have called for HPV testing to be used

2019 CADTH - Optimal Use

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>